Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe Covid-19?

Corticosteroids were the first drugs proven to reduce mortality in Covid-19. In June 2020, the RECOVERY group announced the results of their seminal trial showing dexamethasone 6 mg per day was able to reduce 28-day mortality in hospitalized patients with Covid needing supplemental oxygen or mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Cordeiro Veiga, Viviane, Biasi Cavalcanti, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248174/
https://www.ncbi.nlm.nih.gov/pubmed/35777764
http://dx.doi.org/10.1183/13993003.01220-2022
Descripción
Sumario:Corticosteroids were the first drugs proven to reduce mortality in Covid-19. In June 2020, the RECOVERY group announced the results of their seminal trial showing dexamethasone 6 mg per day was able to reduce 28-day mortality in hospitalized patients with Covid needing supplemental oxygen or mechanical ventilation [1]. Meta-analysis from randomized controlled trials (RCT) in Covid-19 patients confirmed RECOVERY results [2]. In those RCTs, corticosteroid doses were low (dexamethasone 6 mg per day) or intermediate (dexamethasone up to 20mg per day).

Ejemplares similares